01:11 , Jul 15, 2017 |  BC Extra  |  Company News

Management tracks

Immunotherapy company Advaxis Inc. (NASDAQ:ADXS) said President and CEO Daniel O’Connor resigned. CBO Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB (Stockholm, Sweden) named Matthew Gantz...
22:48 , May 15, 2017 |  BC Extra  |  Financial News

Genoa's series A brings in $62M

Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) said it raised $62 million in a series A financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners . Also participating were Novo A/S (Hellerup,...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Amikacin Fosfomycin Inhalation System: Phase II started

Cardeas began the double-blind, placebo-controlled, international Phase II IASIS trial to evaluate Amikacin Fosfomycin Inhalation System delivered twice daily using the eFlow Inline Nebulizer System from Pari GmbH (Starnberg, Germany) for 10 days in about...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Amikacin Fosfomycin Inhalation System regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to Amikacin Fosfomycin Inhalation System for adjunctive treatment of mechanically ventilated patients with bacterial pneumonia. The product is now eligible for an additional 5 years of market...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Amikacin/fosfomycin inhalation solution: Phase Ib data

Interim data from 4 mechanically ventilated patients with ventilator-associated pneumonia or ventilator-acquired tracheobronchitis in a double-blind, placebo-controlled Phase Ib trial showed that at 15 minutes after dosing with aerosolized amikacin/fosfomycin, all amikacin sputum concentrations were...
07:00 , May 27, 2013 |  BC Week In Review  |  Financial News

Cardeas Pharma completes venture financing

Cardeas Pharma Corp. , Seattle, Wash.   Business: Infectious   Date completed: 5/22/13   Type: Venture financing   Raised: $34 million   Investors: H.I.G. Capital; Novo A/S; Avalon Ventures; Devon Park Bioventures; WRF Capital; Delphi...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Cardeas Pharma board of directors update

Cardeas Pharma Corp. , Seattle, Wash.   Business: Infectious   Appointed: Aaron Davidson, managing director of H.I.G. BioVentures  ...
00:34 , May 24, 2013 |  BC Extra  |  Financial News

Cardeas raises $34M in series B

Infectious disease company Cardeas Pharma Corp. (Seattle, Wash.) raised $34 million in a series B round led by new investor H.I.G. BioVentures. Existing investors Novo A/S; Avalon Ventures; Devon Park Bioventures; and WRF Capital also...
07:00 , Sep 10, 2012 |  BioCentury  |  Finance

Avalon reloads

Avalon reloads Avalon Ventures closed its largest fund last month at $201.6 million, which the firm will split between life sciences and technology investments. This 10th fund had a $200 million target and the closing...